XML 25 R14.htm IDEA: XBRL DOCUMENT v3.26.3
Notes Payable
9 Months Ended
Sep. 30, 2026
Debt Disclosure [Abstract]  
Notes Payable Notes Payable
The Company has entered into notes payable agreements with third parties. The tables below summarize these agreements as of September 30, 2026 and December 31, 2025, providing details on contractual maturity dates, contractual interest rates, unpaid principal balances, fair value adjustments, original issue discounts, including proceeds allocated to warrants, and net carrying values.
On September 29, 2025, the Company obtained control of FFR. Accordingly, FFR’s assets and liabilities, including its outstanding debt instruments, have been consolidated as of September 29, 2025. The inclusion of FFR’s debt in the consolidated balances below reflects the fair value of such obligations recognized upon initial consolidation.
Most of the Company’s notes payable are accounted for under the fair value option in accordance with ASC 825, with changes in fair value recorded in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. For instruments measured at fair value, no effective interest rate is presented, as changes in fair value capture all economic returns associated with these debt instruments. Although the stated interest rates on the SPA Portfolio Notes varied between 3.5% and 15%, the Company’s effective cost of capital is substantially higher. Each SPA Portfolio Note permited the holder to settle in shares at a value exceeding the stated principal and accrued interest. In addition, each noteholder received an SPA Portfolio Warrant, and certain holders receive an Incremental Warrant. These settlement features and additional instruments had significant value and materially increased the effective cost of capital above the stated rates. Further, these instruments carry high interest rate structures and embedded economics that can result in a loss on issuance. The financial impact of the SPA Portfolio Notes is reflected in the change in fair value and loss on extinguishment line items in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
September 30, 2026
(in thousands)Contractual
Maturity Date
Contractual
Interest
Rates
Unpaid Principal
Balance
Fair Value
Measurement
Adjustments (Period-End Balance)
(1)Original Issue Discount and Proceeds Allocated to Warrants (Period-End Balance)(1)Net
Carrying
Value
2023 Unsecured SPA NotesVarious through April 203210 %/15%$3,200 $244 $(320)$3,124 
Junior Secured SPA NotesVarious through December 203010%2,627 (989)— 1,638 
2024 Unsecured SPA NotesJuly 203010%33 (11)— 22 
2025 March Unsecured SPA NotesVarious through August 203110%9,688 (4,675)(2,763)2,250 
2025 July Unsecured SPA NotesVarious through August 203110%16,325 (7,317)(1,640)7,368 
Secured Streeterville NotesApril 20283.5 %/9%45,780 (2)871 (750)45,901 
May 2026 Convertible NotesMarch 2027/May 20270%/8%21,106 (4,123)(1,563)15,420 
Notes payable – China other
Due on Demand—%4,475 — — 4,475 
$103,234 $(16,000)$(7,036)$80,198 
Notes payable, current portion$19,895 
Notes payable, long-term portion$60,303 
(1) The amounts presented in the "Fair Value Measurement Adjustments" and "Original Issue Discount and Proceeds Allocated to Warrants" columns represent period-end balances relating to notes outstanding at each reporting date, rather than changes during the reporting periods.
(2) Principal amounts exclude accrued and unpaid interest. Interest on the Secured Streeterville B Note with a principal of $30,000 thousand compounds daily; accrued interest is excluded from the principal amounts presented for all notes
December 31, 2025
(in thousands)Contractual
Maturity Date
Contractual
Interest
Rates
Unpaid Principal
Balance
Fair Value
Measurement
Adjustments (Period-End Balance)
(1)Original Issue Discount and Proceeds Allocated to Warrants (Period-End Balance)(1)Net
Carrying
Value
2023 Unsecured SPA NotesVarious through November 203110%/15%8,100(622)(810)6,668
Junior Secured SPA NotesVarious through December 203010%12,107(705)—11,402
2024 Unsecured SPA NotesVarious through December 203010%6,070(252)—5,818
2025 March Unsecured SPA NotesVarious dates in 203010 %5,508(1,096)(2,304)2,108
2025 July Unsecured SPA NotesAugust 203010 %37,592(3,079)(7,717)26,796
Unsecured Convertible NotesJune 20264.27%5,000(1,558)—3,442
Notes payable – China other
Due on Demand—%4,290——4,290
2025 Convertible Note - FFRJanuary 2026—%13232(22)142
$78,799$(7,280)$(10,853)$60,666
Notes payable, current portion$4,432
Notes payable, long-term portion$56,234
(1) The amounts presented in the "Fair Value Measurement Adjustments" and "Original Issue Discount and Proceeds Allocated to Warrants" columns represent period-end balances relating to notes outstanding at each reporting date, rather than changes during the reporting periods.
Roll Forward of the Fair Value of Notes payable
The following table presents a roll forward of the Company’s Notes payable balances from June 30, 2026 to September 30, 2026 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions.
Categories of Debt
(in thousands)2023
Unsecured
SPA Notes
Unsecured
Convertible
Notes
Junior
Secured
SPA Notes
2024
Unsecured
SPA Notes
2025 March Unsecured SPA Notes2025 July Unsecured SPA NotesNotes 
payable 
–
China other
Streeterville Secured NotesMay 2026 Convertible NotesTotal
Balance as of June 30, 2026 (a)$4,243 $4,943 $4,603 $38 3,373 11,655 $4,421 $43,096 $23,556 $99,928 
New Issuances (b)— 2,192 — — 387 — — — — 2,579 
Repayment of Debt (c)— — — — — (500)— — (5,000)(5,500)
Conversion of Debt to Equity (d)(1,267)— (1,821)— — (5,573)— — (1,025)(9,686)
Extinguishments of Debt (e)— — — — — 320 — — 1,330 1,650 
Fair Value Adjustments of Debt (f)148 (1,098)(1,144)(16)(1,510)(4,571)— 2,805 (3,441)(8,827)
Reclassification of Debt Between Debt Categories (g)— (6,037)— — — 6,037 — — — — 
Other Adjustments (h)— — — — — — 54 — — 54 
Balance as of September 30, 2026 (i)$3,124 $— $1,638 $22 $2,250 $7,368 $4,475 $45,901 $15,420 $80,198 
(a) The carrying value for each note category, fair value or amortized cost depending on the election, as of June 30, 2026.
(b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For notes measured at fair value, the aggregate fair value adjustment recognized at issuance reduced the principal amount of notes issued during the period by $1,920 thousand. This reduction reflects the allocation of total transaction proceeds between the SPA Notes and the related SPA Warrants and Incremental Warrants issued as part of the bundled transaction.
(c) Cash repayments during the period.
(d) Fair value of debt converted into equity during the period.
(e) Adjustments from amendments, modifications, or extinguishment of existing debt, in accordance with ASC 470-50, and presented as a component of 'Loss on settlement of notes payable' in the Consolidated Statements of Operations.
(f) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Line-item Change in fair value of notes payable, warrant liabilities, and derivative call options also includes debt issuance costs of $381 thousand, which are separately identifiable from the fair value adjustments noted above. Instruments with a zero balance in this line are carried at amortized cost; the fair value option was not elected for such instruments.
(g) Transfers of fair value between debt categories resulting from non-cash exchanges of Unsecured Convertible Notes for 2025 July Unsecured SPA Notes during the period.
(h) Miscellaneous changes not captured in other columns, such as currency adjustments and reclassification to accrued expenses.
(i) The carrying value for each note category, fair value or amortized cost depending on the election, as of September 30, 2026.
The following table presents a roll forward of the Company’s Notes payable balances from June 30, 2025 to September 30, 2025 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions.
Categories of Debt
(in thousands)Secured
SPA Notes
2023
Unsecured
SPA Notes
Junior
Secured
SPA Notes
2024
Unsecured
SPA Notes
2025 March Unsecured SPA Notes2025 July Unsecured SPA NotesNotes 
payable 
–
China other
2025 Convertable Note - FFRPromissory Notes - FFRTotal
Balance as of June 30, 2025 (a)$— $4,539 $— $10,009 $9,297 $— $4,188 $— $— $28,033 
New Issuances (b)— 4,500 17,423 21,859 5,103 38,564 — — — 87,449 
Addition of Debt upon Consolidation of FFR (c)— — — — — — — 340 2,897 3,237 
Conversion of Debt to Equity (d)— (1,757)— (15,809)(4,202)— — — — (21,768)
Fair Value Adjustments of Debt (e)— 212 106 (6,233)(2,987)(9,172)— — — (18,074)
Other Adjustments (f)— — — — — — 25 — — 25 
Balance as of September 30, 2025 (h)$— $7,494 $17,529 $9,826 $7,211 $29,392 $4,213 $340 $2,897 $78,902 
(a) The carrying value for each note category, fair value or amortized cost depending on the election, as of June 30, 2025.
(b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For those measured at fair value, the aggregate fair value adjustment at issuance represented an increase of $3,130 thousand to the principal amount of the notes issued during the period, presented as a component of 'Change in fair value of notes payable, warrant liabilities, and call option derivatives' in the Unaudited Condensed Consolidated Statements of Operations.
(c) Represents the addition of FFR’s outstanding debt instruments upon consolidation on September 29, 2025. The FFR debt instruments were recognized at fair value on the acquisition date. For the FFR promissory notes, historical carrying value is deemed to approximate fair value.
(d) Fair value of debt converted into equity during the period.
(e) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of 'Change in fair value of notes payable, warrant liabilities, and call option derivatives' in the Unaudited Condensed Consolidated Statements of Operations. Line item 'Change in fair value of notes payable, warrant liabilities, and call option derivatives' also includes debt issuance costs of $3,063 thousand, which are separately identifiable from the fair value adjustments noted above.
(f) Miscellaneous changes not captured in other columns, such as currency adjustments and reclassification to accrued expenses.
(g) The carrying value for each note category, fair value or amortized cost depending on the election, as of September 30, 2025.
Roll Forward of the Fair Value of Notes payable
The following table presents a roll forward of the Company’s Notes payable balances from December 31, 2025 to September 30, 2026 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions.
Categories of Debt
(in thousands)2023
Unsecured
SPA Notes
Unsecured
Convertible
Notes
Junior
Secured
SPA Notes
2024
Unsecured
SPA Notes
2025 March Unsecured SPA Notes2025 July Unsecured SPA NotesNotes 
payable 
–
China other
Secured Streeterville NotesMay 2026 Convertible Notes2025 Convertible Note - FFRTotal
Balance as of December 31, 2025 (a)$6,668 $3,442 $11,402 $5,818 $2,108 26,796 $4,290 $— $— $142 $60,666 
New Issuances (b)4,050 3,292 — — 2,290 — — 45,000 25,000 — 79,632 
Repayment of Debt (c)— — — — — (500)— — (5,000)(132)(5,632)
Conversion of Debt to Equity (d)(8,703)— (9,547)(6,300)(656)(23,412)— — (1,025)— (49,643)
Extinguishments of Debt (e)— — — — — 320 — — 1,330 — 1,650 
Fair Value Adjustments of Debt (f)1,109 (697)(217)504 (1,492)(1,873)— 901 (4,885)(10)(6,660)
Reclassification of Debt Between Debt Categories (g)— (6,037)— — — 6,037 — — — — — 
Other Adjustments (h)— — — — — — 185 — — — 185 
Balance as of September 30, 2026 (i)$3,124 $— $1,638 $22 $2,250 $7,368 $4,475 $45,901 $15,420 $— $80,198 
(a) The carrying value for each note category, fair value or amortized cost depending on the election, as of December 31, 2025.
(b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For notes measured at fair value, the aggregate fair value adjustment recognized at issuance reduced the principal amount of notes issued during the period by $8,368 thousand. This reduction reflects the allocation of total transaction proceeds between the SPA Notes and the related SPA Warrants and Incremental Warrants issued as part of the bundled transaction.
(c) Cash repayments during the period.
(d) Fair value of debt converted into equity during the period.
(e) Adjustments from amendments, modifications, or extinguishment of existing debt, in accordance with ASC 470-50, and presented as a component of 'Loss on settlement of notes payable' in the Consolidated Statements of Operations.
(f) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Line-item Change in fair value of notes payable, warrant liabilities, and derivative call options also includes debt issuance costs of $7,038 thousand, which are separately identifiable from the fair value adjustments noted above. Instruments with a zero balance in this line are carried at amortized cost; the fair value option was not elected for such instruments.
(g) Transfers of fair value between debt categories resulting from non-cash exchanges of Unsecured Convertible Notes for 2025 July Unsecured SPA Notes during the period.
(h) Miscellaneous changes not captured in other columns, such as currency adjustments and reclassification to accrued expenses.
(i) The carrying value for each note category, fair value or amortized cost depending on the election, as of September 30, 2026.
The following table presents a roll forward of the Company’s Notes payable balances from December 31, 2024 to September 30, 2025 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions.
Categories of Debt
(in thousands)Secured
SPA Notes
2023
Unsecured
SPA Notes
Junior
Secured
SPA Notes
2024
Unsecured
SPA Notes
2025 March Unsecured SPA Notes2025 July Unsecured SPA NotesNotes 
payable 
–
China other
2025 Convertable Note - FFRPromissory Notes - FFRAuto
Loans
Total
Balance as of December 31, 2024 (a)$5,457 $6,716 $26,059 $7,032 $— $— $4,173 $— $— $51 $49,488 
New Issuances (b)— 9,000 17,423 32,955 15,197 38,564 — — — — 113,139 
Addition of Debt upon Consolidation of FFR (c)— — — — — — — 340 2,897 — 3,237 
Repayment of Debt (d)— — — — — — — — — (6)(6)
Conversion of Debt to Equity (e)(3,535)(6,449)(16,468)(21,656)(7,712)— — — — — (55,820)
Fair Value Adjustments of Debt (f)(1,922)(1,773)(9,485)(8,505)(274)(9,172)— — — — (31,131)
Other Adjustments (g)— — — — — — 40 — — (45)(5)
Balance as of September 30, 2025 (h)$— $7,494 $17,529 $9,826 $7,211 $29,392 $4,213 $340 $2,897 $— $78,902 
(a) The carrying value for each note category, fair value or amortized cost depending on the election, as of December 31, 2024.
(b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For those measured at fair value, the aggregate fair value adjustment at issuance represented a reduction of $20,250 thousand to the principal amount of the notes issued during the period, presented as a component of 'Change in fair value of notes payable, warrant liabilities, and call option derivatives' in the Unaudited Condensed Consolidated Statements of Operations.
(c) Represents the addition of FFR’s outstanding debt instruments upon consolidation on September 29, 2025. The FFR debt instruments were recognized at fair value on the acquisition date. For the FFR promissory notes, historical carrying value is deemed to approximate fair value.
(d) Cash repayments during the period.
(e) Fair value of debt converted into equity during the period.
(f) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of 'Change in fair value of notes payable, warrant liabilities, and call option derivatives' in the Unaudited Condensed Consolidated Statements of Operations. Line item 'Change in fair value of notes payable, warrant liabilities, and call option derivatives' also includes debt issuance costs of $5,293 thousand, which are separately identifiable from the fair value adjustments noted above.
(g) Miscellaneous changes not captured in other columns, such as currency adjustments and reclassification to accrued expenses.
(h) The carrying value for each note category, fair value or amortized cost depending on the election, as of September 30, 2025.
Schedule of Principal Maturities of Notes Payable
The future scheduled principal maturities of Notes payable as of September 30, 2026, are as follows:
(in thousands)
Due on demand$4,475 
2026— 
202721,106 
202845,780 
2029— 
203010,648 
203118,025 
Thereafter3,200 
$103,234 
The Company has issued various financing arrangements, including secured and unsecured notes, convertible notes, and loans. These are categorized as follows: (i) Secured SPA Notes; (ii) 2023 Unsecured SPA Notes; (iii) Unsecured Convertible Notes; (iv) Junior Secured SPA Notes; (v) 2024 Unsecured SPA Notes; (vi) 2025 March Unsecured SPA Notes; (vii) 2025 July Unsecured SPA Notes; (viii) Notes payable – China other; (ix) Auto loans, (x) 2026 May Convertible SPA Notes, and (xi) Secured Streeterville Notes. In addition, the Company consolidated FFR effective September 29, 2025, and accordingly recognized FFR’s outstanding debt instruments at fair value as of the consolidation date. These obligations are included within the categories presented above.
Below is a discussion of the terms, amendments, letter agreements, and financial impacts for each category of debt.
Secured SPA Notes
Overview and Terms
The Secured SPA Notes were issued under the securities purchase agreement (the “Secured SPA”) dated August 14, 2022, with FF Simplicity Ventures LLC (“FFSV”) acting as administrative agent, collateral agent, and purchaser, along with additional purchasers. These senior secured convertible notes are supported by a second lien on substantially all of the Company’s assets and are guaranteed by the Company’s domestic subsidiaries.
The Secured SPA Notes bear an annual interest rate of 10%, increasing to 15% if interest is paid in shares of Class A Common Stock. Principal and interest are due at maturity, unless converted earlier pursuant to the Secured SPA Notes’ conversion privileges. The Secured SPA Notes mature nine years from each date of issuance. Issued at a 10% original issue discount, these notes are convertible into Class A Common Stock at the lesser of a fixed conversion price or 90% of the lowest volume-weighted average price (“VWAP”) for the trading day immediately prior to the conversion date. The Secured SPA Notes are subject to full ratchet anti-dilution price protection; at the time of the final conversions the fixed conversion price was $174.00, as adjusted for the Reverse Stock Split. There were no outstanding Secured SPA Notes, as of September 30, 2026.
In connection with the issuance of the Secured SPA Notes, the Company also granted to each purchaser a warrant (the “Secured SPA Warrants”) to purchase shares of Class A Common Stock equal to 33% of the shares issuable upon conversion of the aggregate principal amount under the Secured SPA Notes funded. The Secured SPA Warrants are subject to the same full ratchet anti-dilution price protection as the Secured SPA Notes. The Secured SPA Warrants are indexed to the Company’s Class A Common Stock and, as such, meet the scope exception in ASC 815-40 to be classified within equity.
The Company elected the fair value option afforded by ASC 825, Financial Instruments, with respect to the Secured SPA Notes because the notes include features, such as a contingently exercisable put option, that meet the definition of an embedded derivative. The Company expenses transaction costs to Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company also elected to apply the fair value option for all other SPA Portfolio Notes.
Summary of Secured SPA Notes Activity
As of September 30, 2026 and December 31, 2025, the fair value of the Secured SPA Notes was zero.
There was no activity related to the Secured SPA Notes during the three and nine months ended September 30, 2026. During the three months ended September 30, 2025 ,the Company received zero cash proceeds, after original issue discounts, in exchange for the issuance of Secured SPA Notes. During the same period, the Company converted debt with a principal amount of zero into no shares of Class A Common Stock, as adjusted for the reverse Stock Split. The conversion of Secured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of zero. For the three months ended September 30, 2025, the Company recognized a loss of zero from the fair value remeasurement of Secured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the nine months ended September 30, 2025 ,the Company received zero cash proceeds, after original issue discounts, in exchange for the issuance of Secured SPA Notes. During the same period, the Company converted debt with a principal amount of $3.1 million into 21,099 shares of Class A Common Stock, as adjusted for the reverse Stock Split. The conversion of Secured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of $0.3 million. For the nine months ended September 30, 2025, the Company recognized a gain of $1.9 million, from the fair value remeasurement of Secured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
2023 Unsecured SPA Notes
Overview and Terms
Pursuant to that certain Securities Purchase Agreement dated May 8, 2023, (the “2023 Unsecured SPA”) by and between the Company and the investors party thereto, including Metaverse Horizon Limited (“MHL”), a related party, the Company issued certain unsecured convertible promissory note (the “2023 Unsecured SPA Notes”). These 2023 Unsecured SPA Notes are unsecured and have terms similar to the Secured SPA Notes, except they lack collateral backing.
The 2023 Unsecured SPA Notes bear an annual interest rate of 10%, increasing to 15%, if interest is paid in shares of Class A Common Stock. Principal and interest are due at maturity, unless converted earlier pursuant to the 2023 Unsecured SPA Notes’ conversion privileges. Issued at a 10% original issue discount, these notes are convertible into the Company’s Class A Common Stock at the lesser of a fixed conversion price or 90% of the VWAP for the trading day immediately prior to the conversion date. The 2023 Unsecured SPA Notes are subject to full ratchet anti-dilution price protection and as of September 30, 2026 the fixed conversion price was $1.18, as adjusted for the Reverse Stock Split. The 2023 Unsecured SPA Notes mature primarily six years from each date of issuance.
In connection with the issuance of the 2023 Unsecured SPA Notes, the Company also granted to each purchaser a warrant (the “2023 Unsecured SPA Warrants”) to purchase shares of Class A Common Stock equal to 33% of the shares issuable upon conversion of the aggregate principal amount under the Secured SPA Notes funded. The 2023 Unsecured SPA Warrants are subject to the same full ratchet anti-dilution price protection as the 2023 Unsecured SPA Notes. The 2023 Unsecured SPA Warrants are indexed to the Company’s Class A Common Stock and, as such, meet the scope exception in ASC 815-40 to be classified within equity.
Anti-Dilution Adjustments
During the year ended December 31, 2025, the Company entered into several dilutive sale and purchase transactions through issuance of Junior Secured SPA Notes, 2024 Unsecured SPA Notes, March 2025 Unsecured Notes and July 2025 Unsecured Notes. These transactions triggered the full ratchet anti-dilution price protection for the 2023 Unsecured SPA Notes issued prior to each respective dilutive transaction.
During the three months ended June 30, 2026, the Company converted certain Junior Secured SPA Notes into shares of Class A Common Stock at conversion prices below the then-effective fixed conversion price of the outstanding 2023 Unsecured SPA Notes. These conversions constituted dilutive issuances that triggered the full ratchet anti-dilution price protection for the outstanding 2023 Unsecured SPA Notes. Accordingly, the conversion price of outstanding 2023 Unsecured SPA Notes was $1.18, as adjusted for the Reverse Stock Split.
Summary of 2023 Unsecured SPA Notes Activity
As of September 30, 2026, the fair value of the outstanding 2023 Unsecured SPA Notes was $3.1 million, compared to $6.7 million as of December 31, 2025.
During the three months ended September 30, 2026, and 2025, the Company received net cash proceeds of zero and $4.5 million, respectively, after original issue discounts, in exchange for the issuance of 2023 Unsecured SPA Notes. During the same periods, the Company converted debt with a principal amount of $1.3 million and $1.9 million into 1,128,268 and 10,816 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of 2023 Unsecured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of $0.5 million and $0.4 million for each period, respectively. For the three months ended September 30, 2026, and 2025, the Company recognized a loss of $0.1 million and $0.2 million, respectively, from the fair value remeasurement of 2023 Unsecured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the nine months ended September 30, 2026 and 2025, the Company received net cash proceeds of $4.1 million and $9.0 million, respectively, after original issue discounts, in exchange for the issuance of 2023 Unsecured SPA Notes. During the same periods, the Company converted debt with a principal amount of $9.4 million and $6.3 million into 1,299,018 and 38,601 shares of Class A Common Stock, as adjusted for the reverse Stock Split, respectively. The conversion of 2023 Unsecured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of $3.3 million and $3.2 million for each period, respectively. For the nine months ended September 30, 2026 and 2025, the Company recognized a loss of $1.1 million and a gain of $1.8 million, respectively, from the fair value remeasurement of 2023 Unsecured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
Unsecured Convertible Notes
Overview and Terms
During the year ended December 31, 2025 and the nine months ended September 30, 2026, the Company issued unsecured convertible notes (the “Unsecured Convertible Notes”) to a third party investor. These Unsecured Convertible Notes, mature six months from issuance, accrue interest at 4.27% and are convertible into 2025 July Unsecured SPA Notes upon the subsequent closing of such Notes.
On June 29, 2026, the Company entered into an unsecured convertible loan agreement with Lumina Investment International Ltd. ("Lumina") for $1.3 million, which was funded on July 2, 2026. Additional loans dated July 10 and August 10, 2026, each for $1.1 million, were funded on July 13 and August 14, 2026, respectively. These loans bore interest at 4.27% per annum, matured six months from funding and were convertible at the holder's option into 2025 July Unsecured SPA Notes. The $3.5 million of loans funded during the third quarter were exchanged into 2025 July Unsecured SPA Notes on August 21, 2026.
In 2024, the Company issued unsecured convertible notes (the “Unsecured Convertible Notes”) to various investors, including MHL, a related party. These Unsecured Convertible Notes, mature three months from issuance, accrue interest at 4.27% and are convertible at issuance into Class A Common Stock, certain SPA Portfolio Notes, or a future security purchase agreement issued by the Company. The activity below does not include related parties activity, discussed separately in Note 9, Related Party Transactions.
The Company elected the fair value option afforded by ASC 825, Financial Instruments, with respect to the Unsecured Convertible Notes because the notes are exchangeable into SPA Portfolio Notes and the Company expects that to be how the Unsecured Convertible Notes settle. The Company expenses transaction costs to Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
Summary of Unsecured Convertible Notes Activity
As of September 30, 2026, the fair value of the outstanding Unsecured Convertible Notes was zero, compared to $3.4 million as of December 31, 2025.
The Unsecured Convertible Notes were exchanged into 2025 July Unsecured SPA Notes at the July 31 and August 21, 2026 closings described below. No Unsecured Convertible Notes remained outstanding as of September 30, 2026.
During the three months ended September 30, 2026, and 2025, the Company received net cash proceeds of $3.5 million and zero, respectively, after original issue discounts, in exchange for the issuance of Unsecured Convertible Notes. During the same periods, the Company neither converted any Unsecured Convertible Notes into shares of Class A Common Stock, nor incurred gain or a loss on extinguishment for each period. For the three months ended September 30, 2026, and 2025, the Company recognized a gain of $1.1 million and zero, respectively, from the fair value remeasurement of Unsecured Convertible Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the nine months ended September 30, 2026 and 2025, the Company received net cash proceeds of $5.0 million and zero, respectively, after original issue discounts, in exchange for the issuance of Unsecured Convertible Notes. During the same periods, the Company neither converted any Unsecured Convertible Notes into shares of Class A Common Stock, nor incurred gain or a loss on extinguishment for each period. For the nine months ended September 30, 2026 and 2025, the Company recognized a gain of $0.7 million and zero, respectively, from the fair value remeasurement of Unsecured Convertible Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
Junior Secured SPA Notes
Overview and Terms
Pursuant to that certain Securities Purchase Agreement dated September 5, 2024 by and between the Company and the investors party thereto (the “Junior Secured SPA”), the Company issued certain secured convertible promissory notes (the “Junior Secured SPA Notes”). These Junior Secured SPA Notes are secured by a second-priority lien on certain assets and bear an annual interest rate of 10%. Principal and interest are payable at maturity or at each conversion date. The notes are convertible along with accrued interest into Class A Common Stock at the lesser of (a) a fixed conversion price or (b) the
greater of (1) the floor price of $5.00, as adjusted for the reverse Stock Split, or (2) the average VWAP of the common stock for the five previous trading days. Junior Secured SPA Notes are subject to full ratchet anti-dilution price protection and as of September 30, 2026 the fixed conversion prices were $1.18, as adjusted for the Reverse Stock Split, depending on the tranches outstanding. These notes mature on various dates through December 2030.
The original Junior Secured SPA Investors were given warrants (the “Junior SPA Warrants”) equal to 100% of the shares issuable upon conversion of the aggregate principal amount under the Junior Secured SPA Note funded. The Junior SPA Warrants are exercisable immediately with a term of five years. The Company issued to the placement agent for the transaction a warrant (the “Placement Agent Warrant”) identical to that of the Junior Secured SPA Investors for 1,352 shares of Common Stock, as adjusted for the Reverse Stock Split, exercisable immediately. These warrants are subject to the same full ratchet anti-dilution price protection as the Junior Secured SPA Notes. As of September 30, 2026, the Company’s Junior Secured SPA Warrants are indexed to the Company’s Class A common stock and meet the requirements for equity classification under the scope exception in ASC 815-40.
The Junior Secured SPA Investors were issued incremental warrants (the “Junior Secured SPA Incremental Warrants”) to purchase additional Junior Secured SPA Notes up to the amounts originally funded under their original Junior Secured SPA Note commitments. The Junior Secured SPA Incremental Warrants, presented in the Unaudited Condensed Consolidated Balance Sheets as Derivative call options, are exercisable immediately upon issuance and have a one-year term. They allow the purchase of the respective notes at an exercise price equal to the principal amount of the notes issued to the investor, subject to full ratchet anti-dilution price protection, as adjusted for stock splits, stock dividends, stock combinations, recapitalizations, or similar transactions. There were no Junior Secured SPA Incremental Warrants outstanding as of September 30, 2026.
Amendments and Modifications
•Letter Agreements: On January 28, 2025, the Company entered into a letter agreement (the “September Letter Agreement”) with certain Junior Secured SPA Investors. These investors agreed not to convert outstanding notes below the initial conversion price of $786.00, as adjusted for the Reverse Stock Slit, prior to the Company’s receipt of stockholder approval for the issuance of the Junior Secured SPA Notes, Junior SPA Warrants and Junior SPA Incremental Warrants. In return, the Company agreed to issue “True-Up Shares” after approval to adjust for any pre-approval conversions, based on a formula considering accrued interest and market pricing. The September Letter Agreement include a provision preventing the issuance of shares of common stock underlying the applicable securities if the Company's available authorized stock is insufficient. However, the Company must deliver the shares once a sufficient number of authorized but unissued shares becomes available.
Anti-Dilution Adjustments
On December 21, 2024, the Company entered into the 2024 Unsecured SPA (as defined below), pursuant to which the Company issued certain 2024 Unsecured SPA Notes to the purchasers party thereto, which triggered the full ratchet anti-dilution price protection in the Junior Secured SPA Notes and Junior Secured SPA Warrants. The issuance of the 2024 Unsecured SPA Notes constituted a dilutive issuance, as the stated conversion price of $174.00, as adjusted for the Reverse Stock Split, was less than the Junior Secured SPA Notes conversion and Junior Secured SPA Warrant exercise price.
During the year ended December 31, 2025, the Company issued additional 2024 Unsecured SPA Notes upon the exercise of 2024 Unsecured SPA Incremental Warrants with a stated conversion price of $174.00, as adjusted for the Reverse Stock Split. These transactions triggered the full ratchet anti-dilution provisions for any incremental Junior Secured SPA Notes issued prior to such dilutive issuances, maintaining the ratcheted fixed conversion price at the same split-adjusted price.
During the three and nine months ended September 30, 2026 the Company converted certain 2023 Unsecured SPA Notes at conversion prices below the then-effective fixed conversion price of the outstanding Junior Secured SPA Notes, constituting further dilutive issuances that triggered the full ratchet anti-dilution provisions of Junior Secured SPA Notes. As a result, the fixed conversion price of outstanding Junior Secured SPA Notes as of September 30, 2026 was $1.18, as adjusted for the Reverse Stock Split.
Summary of Junior Secured SPA Notes Activity
As of September 30, 2026, the fair value of the Junior Secured SPA Notes was $1.6 million, compared to $11.4 million as of December 31, 2025.
During the three months ended September 30, 2026, and 2025, the Company received zero and $18.0 million net cash proceeds, after original issue discounts, in exchange for the issuance of Junior Secured SPA Notes. During the same periods,
the Company converted debt with a principal amount of $2.1 million and zero into 699,185 and 0 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of Junior Secured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of $0.2 million and zero, for the respective periods. For the three months ended September 30, 2026, and 2025, the Company recognized a gain of $1.1 million and a loss of $0.1 million, respectively, from the fair value remeasurement of Junior Secured SPA Notes under ASC 825, which were recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the nine months ended September 30, 2026 and 2025, the Company received no and 18.0 million net cash proceeds, after original issue discounts, in exchange for the issuance of Junior Secured SPA Notes. During the same periods, the Company converted debt with a principal amount of $9.5 million and $28.8 million into 881,278 and 182,750 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of Junior Secured SPA Notes into Class A Common Stock resulted in loss on extinguishment of $2.1 million and $20.4 million, for the respective periods. For the nine months ended September 30, 2026 and 2025, the Company recognized gains of $0.2 million and $9.5 million, respectively, from the fair value remeasurement of Junior Secured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
2024 Unsecured SPA Notes
Overview and Terms
The 2024 Unsecured SPA Notes were issued under a securities purchase agreement (the “2024 Unsecured SPA”) dated December 21, 2024, by and between the Company and the investors party thereto. These notes bear an annual interest rate of 10%. Principal and interest are payable at maturity or at each conversion date. The notes are convertible along with accrued interest into Class A Common Stock at the lesser of (a) a fixed conversion price, which was $174.00, as adjusted for the Reverse Stock Split, or (b) the greater of (1) the floor price, $157.20, as adjusted for the reverse Stock Split, or (2) the lowest one-day VWAP of the common stock for the five previous trading days. 2024 Unsecured SPA Notes are subject to full ratchet anti-dilution price protection and as of September 30, 2026 the fixed conversion price of the outstanding 2024 Unsecured SPA Notes was $1.18, as adjusted for the reverse Stock Split. These notes mature in July 2030.
The original 2024 Unsecured SPA Investors were issued warrants (the “2024 Unsecured SPA Warrants”) equal to 100% of the shares issuable upon conversion of the aggregate principal amount under the 2024 Unsecured SPA Notes (defined below) purchased by such 2024 Unsecured SPA Investor. The 2024 Unsecured SPA Warrants are exercisable immediately with a term of five years. 2024 Unsecured SPA Warrants are subject to the same full ratchet anti-dilution price protection as the 2024 Unsecured SPA Notes. As of September 30, 2026, the Company’s 2024 Unsecured SPA Warrants are indexed to the Company’s Class A common stock and meet the requirements for equity classification under the scope exception in ASC 815-40.
The original 2024 Unsecured SPA Investors were issued incremental warrants (the “2024 Unsecured SPA Incremental Warrants”) to purchase additional 2024 Unsecured SPA Notes up to the amounts originally funded under their original 2024 Unsecured SPA Note commitments. The 2024 Unsecured SPA Incremental Warrants, presented in the Unaudited Condensed Consolidated Balance Sheets as Derivative call options, are exercisable immediately upon issuance and have a one-year term. They allow the purchase of the respective notes at an exercise price equal to the principal amount of the notes issued to the investor, subject to full ratchet anti-dilution price protection, as adjusted for stock splits, stock dividends, stock combinations, recapitalizations, or similar transactions. See Note 15, Fair Value of Financial Instruments for further details on the 2024 Unsecured SPA Incremental Warrants. There were no 2024 Unsecured SPA Incremental Warrants outstanding as of September 30, 2026.
Amendments and Modifications
•Letter Agreements: On January 28, 2025, the Company entered into a letter agreement (the “December Letter Agreement”) with certain 2024 Unsecured SPA Investors, modifying terms related to their previously disclosed investment. These investors agreed not to convert outstanding notes below the initial conversion price of $174.00, as adjusted for the reverse Stock Split, before stockholder approval for the issuance of the 2024 Unsecured SPA Notes, 2024 Unsecured SPA Warrants and 2024 Unsecured Incremental Warrants. The Company agreed to issue True-Up Shares post-approval using an adjustment formula. Additionally, if a resale registration statement becomes effective, and the conversion price exceeds the prior day's closing bid price, the conversion price will be adjusted downward. The December Letter Agreement includes a provision preventing the issuance of shares of common stock underlying
the applicable securities if the Company's available authorized stock is insufficient. However, the Company must deliver the shares once sufficient stock becomes available.
Anti-Dilution Adjustments
During the three and nine months ended September 30, 2026 the Company converted certain 2023 Unsecured SPA Notes and 2025 July Unsecured SPA Notes (as defined below) at conversion prices below $174.00 per share, as adjusted for the Reverse Stock Split, constituting dilutive issuances that triggered the full ratchet anti-dilution provisions of 2024 Unsecured SPA Notes, issued prior to the issuance of the respective 2023 Unsecured SPA Notes and 2025 July Unsecured SPA Notes whose conversions gave rise to the ratchet adjustments. As a result, the fixed conversion price of outstanding 2024 Unsecured SPA Notes as of September 30, 2026 was reduced to $1.18 per share, as adjusted for the Reverse Stock Split.
Summary of 2024 Unsecured SPA Notes Activity
As of September 30, 2026, the fair value of the 2024 Unsecured SPA Notes was $22.0 thousand, compared to $5.8 million as of December 31, 2025.
During the three months ended September 30, 2026, and 2025, the Company received no and $14.0 million net cash proceeds, after original issue discounts, in exchange for the issuance of 2024 Unsecured SPA Notes. During the same periods, the Company converted debt with a principal amount of zero and $23.2 million into zero and 139,294 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of 2024 Unsecured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of zero and $36.3 million, for each period, respectively. For the three months ended September 30, 2026, and 2025, the Company recognized a gain of $16.0 thousand and a gain of $6.2 million, respectively, from the fair value remeasurement of 2024 Unsecured SPA Notes under ASC 825, which were recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the nine months ended September 30, 2026 and 2025, the Company received net cash proceeds of zero and $34.0 million, respectively, after original issue discounts, in exchange for the issuance of 2024 Unsecured SPA Notes. During the same periods, the Company converted debt with a principal amount of $6.0 million and $34.9 million into 76,422 and 211,272 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversions of 2024 Unsecured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of $0.6 million and $45.6 million, for the respective periods. For the nine months ended September 30, 2026 and 2025, the Company recognized a loss of $0.5 million and a gain of $8.5 million, respectively, from the fair value remeasurement of 2024 Unsecured SPA Notes under ASC 825, which were recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
2025 March Unsecured SPA Notes
Overview and Terms
On March 21, 2025, the Company entered into a securities purchase agreement (the “2025 March Unsecured SPA”) with certain accredited investors, including MHL a related party (collectively, the “2025 March Unsecured SPA Investors”), pursuant to which the Company agreed to issue and sell an aggregate of $41.0 million in principal amount of senior unsecured convertible promissory notes (the “2025 March Unsecured SPA Notes”). The 2025 March Unsecured SPA originally provided for four closings, each subject to specified closing conditions including minimum trading price and volume thresholds. The activity below does not include related party activity, discussed separately in Note 9, Related Party Transactions.
The 2025 March Unsecured SPA Notes mature in five years from the date of issuance and bear interest at a fixed rate of 10% per annum. Interest is payable on each conversion date or at maturity and may be settled in cash, shares of Class A common stock, or a combination thereof, at the Company’s election and subject to certain conditions. In the event of a default, the interest rate increases to 18% per annum. The Company may redeem the notes at a premium of 10% over the greater of (i) the value of the shares otherwise issuable upon conversion and (ii) the value of the note’s outstanding principal. In a bankruptcy-related default, the notes are redeemable at a 25% premium, unless waived by the holder.
The 2025 March Unsecured SPA Notes are convertible at the option of the holder into shares of the Company’s Class A common stock at an initial fixed conversion price of $193.50 per share, as adjusted for the Reverse Stock Split, subject to customary anti-dilution adjustments and full ratchet anti-dilution price protection. The number of shares issuable upon conversion is determined by dividing the outstanding principal and accrued interest, together with an 8% premium, by the conversion price. The notes also include an alternate conversion feature that permits the holder to convert at the lower of (i) the
then-effective conversion price or (ii) the greater of the floor price then in effect and the lowest VWAP of the Class A common stock during the five trading days immediately preceding the conversion notice. If a conversion under the alternate mechanism would result in issuance below the floor price, the Company must either settle the difference in cash or increase the principal balance of the note by the shortfall amount. The floor price is subject to reduction at the Company's discretion and was $5.00 per share, as adjusted for the reverse Stock Split, as of September 30, 2026.
The 2025 March Unsecured SPA Investors were issued warrants (the “2025 March Unsecured SPA Warrants”) equal to 100% of the shares issuable upon conversion of the aggregate principal amount under the 2025 March Unsecured SPA Notes funded, calculated using the initial conversion price of the 2025 March Unsecured SPA Notes. The 2025 March Unsecured SPA Warrants are exercisable immediately with a term of five years. The 2025 March Unsecured SPA Warrants are subject to a full ratchet anti-dilution price protection similar to that applicable to the 2025 March Unsecured SPA Notes. As of September 30, 2026, the Company’s issued 2025 March Unsecured SPA Warrants are indexed to the Company’s Class A common stock and meet the requirements for equity classification under the scope exception in ASC 815-40.
The 2025 March Unsecured SPA Investors were issued incremental warrants (the “2025 March Unsecured SPA Incremental Warrants”) to purchase additional 2025 March Unsecured SPA Notes up to the amounts funded under their 2025 March Unsecured SPA commitments. The 2025 March Unsecured SPA Incremental Warrants, presented in the Unaudited Condensed Consolidated Balance Sheets as Derivative call options, are exercisable immediately upon issuance and have a five-year term. They allow the purchase of the respective notes at an exercise price equal to the principal amount of the notes issued to the investor, subject to full ratchet anti-dilution price protection, as adjusted for stock splits, stock dividends, stock combinations, recapitalizations, or similar transactions. See Note 15, Fair Value of Financial Instruments for further details on the 2025 March Unsecured SPA Incremental Warrants.
None of the issued or unissued 2025 March Unsecured SPA Incremental Warrants remained outstanding at September 30, 2026 following the cancellations and terminations described below.
The 2025 March Unsecured SPA Investors received a number of shares of Series B Preferred Stock equal to the lesser of (i) the number of shares of common stock into which such purchaser’s notes are convertible, and (ii) such purchaser’s pro rata share (based on commitment percentage) of an aggregate cap of 9,000,000 shares of Series B Preferred Stock. See Note 13, Stockholders’ Equity for further details regarding the Series B Preferred Stock.
The activity below does not include related party transactions, which are discussed separately in Note 9, Related Party Transactions.
Amendments and Modifications
On May 15, 2025, the Company entered into a Waiver and Amendment Agreement (the “SPA Waiver”) with the 2025 March Unsecured SPA Investors. The SPA Waiver modified certain registration and closing conditions provisions under the SPA, as described below.
Under the SPA Waiver, the Investors agreed that the Company is required to register for resale on the initial registration statement (the “Initial Registration Statement”) only the shares of Class A common stock issuable upon conversion of the 2025 March Unsecured SPA Notes issued at the first closing. The Company is not required to register on the Initial Registration Statement any shares issuable upon exercise of the 2025 March Unsecured SPA Warrants or 2025 March Unsecured SPA Incremental Warrants or securities issued in subsequent closings. However, the Company agreed to use commercially reasonable efforts to file a subsequent registration statement to cover (i) the remaining shares underlying the 2025 March Unsecured Notes, 2025 March Unsecured SPA Warrants, and 2025 March Unsecured SPA Incremental Warrants within 45 calendar days after the later of (a) the effectiveness of the Initial Registration Statement or (b) the date an Investor requests registration, and (ii) shares issuable under instruments from any subsequent closing within 45 calendar days after the later of (a) the effectiveness of the Initial Registration Statement or (b) the applicable closing date.

Under the original terms of the 2025 March Unsecured SPA, if the conditions to a subsequent closing were not satisfied by the scheduled closing date, the closing could be delayed for up to twenty (20) business days. Pursuant to the SPA Waiver, the SPA was amended to provide that if, during such 20-business-day deferral period, the closing price of the Company’s Class A common stock is below $1.00, the applicable subsequent closing shall instead occur within twenty (20) business days following the first trading day on which the closing price equals or exceeds $1.00.
In addition, the Company obtained the right, at its sole discretion, to reduce the portion of a 2025 March Unsecured SPA Investor’s purchase amount to be funded at any individual closing, provided that no such investor’s aggregate commitment is reduced.
On August 20, 2026, the Company amended the 2025 March Unsecured SPA to divide the Fourth Closing into Fourth Closing No. 1 and Fourth Closing No. 2, eliminate common warrants and incremental warrants at the remaining closings, and remove common warrants otherwise issuable upon exercise of existing incremental warrants. The amendment also waived registration-statement effectiveness as a condition to the remaining closings. The stockholder-approval and registration-effectiveness resets remained unchanged.
In connection with the August 20, 2026 amendment, the Company eliminated commitments to issue common warrants to purchase 46,659 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, and incremental warrants exercisable for notes with an aggregate principal amount of $8.5 million. On August 31, 2026, the Company entered into agreements terminating certain outstanding 2025 March Unsecured SPA Incremental Warrants exercisable for notes with an aggregate principal amount of $21.0 million, together with the related rights to receive common warrants and Series B Preferred Stock.
Note Conversion and exercise price re-set
Pursuant to the terms of the 2025 March Unsecured SPA, on May 28, 2025, the fixed conversion price of the 2025 March Unsecured SPA Notes and the exercise price of the related common stock warrants were reset to 100% and 120%, respectively, of the closing price of the Company’s Class A common stock on the trading day immediately prior to the receipt of stockholder approval for the related private placement. As a result, the fixed conversion price and warrant exercise price of the 2025 March Unsecured SPA instruments were re-set to $183.00 and $219.60 per share, as adjusted for the reverse Stock Split, respectively.
During the three months ended September 30, 2026, certain issuances of Class A Common Stock under the Company’s at-the-market offering program and upon conversion of 2023 Unsecured SPA Notes were effected at prices below the then-effective fixed conversion price of the outstanding 2025 March Unsecured SPA Notes. These issuances constituted dilutive transactions that triggered the full ratchet anti-dilution price protection for the outstanding 2025 March Unsecured SPA Notes. Accordingly, after giving effect to the contractual floor-price provisions, the applicable conversion price of the outstanding 2025 March Unsecured SPA Notes as of September 30, 2026 was $5.00 per share, as adjusted for the Reverse Stock Split. Reductions in the floor price to $1.50 and $1.00 per share on September 22 and September 24, 2026, respectively, were rescinded on September 26, 2026. Accordingly, the floor price was $5.00 per share as of September 30, 2026.
Summary of 2025 March Unsecured SPA Notes Activity
As of September 30, 2026, the fair value of the outstanding 2025 March Unsecured SPA Notes, was $2.3 million compared to $2.1 million as of December 31, 2025.
During the three months ended September 30, 2026, and 2025, the Company received net cash proceeds of $1.0 million and $8.1 million, respectively, after original issue discounts, in exchange for the issuance of 2025 March Unsecured SPA Notes. During the same periods, the Company converted debt with principal amounts of zero and $9.3 million into zero and 56,195 shares of Class A Common Stock, as adjusted for the reverse Stock Split, respectively. The conversion of 2025 March Unsecured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of zero and $9.8 million, for the respective periods. For the three months ended September 30, 2026, and 2025, the Company recognized a gain of $1.5 million and a gain of $3.0 million, respectively, from the fair value remeasurement of 2025 March Unsecured SPA Notes under ASC 825, which were recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the nine months ended September 30, 2026 and 2025, the Company received net cash proceeds of $5.7 million and $32.2 million, respectively, after original issue discounts, in exchange for the issuance of 2025 March Unsecured SPA Notes. During the same periods, the Company converted debt with principal amounts of $1.7 million and $16.0 million into 12,252 and 97,326 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of 2025 March Unsecured SPA Notes into Class A Common Stock resulted in a loss on extinguishment of $1.3 million and $15.3 million, for the respective periods. For the nine months ended September 30, 2026 and 2025, the Company recognized gains of $1.5 million and $0.3 million, respectively, from the fair value remeasurement of 2025 March Unsecured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
2025 July Unsecured SPA Notes
Overview and Terms
On July 14, 2025, the Company entered into a securities purchase agreement (the “2025 July Unsecured SPA”) with certain accredited investors (collectively, the “2025 July Unsecured SPA Investors”), pursuant to which the Company agreed to issue and sell an aggregate of $82.0 million in principal amount of senior unsecured convertible promissory notes (the “2025 July Unsecured SPA Notes”). The 2025 July Unsecured SPA originally provided for two closings, each subject to specified closing conditions including minimum trading price and volume thresholds.
The 2025 July Unsecured SPA Notes mature five years from the date of issuance and bear interest at a fixed rate of 10% per annum. Interest is payable on each conversion date or at maturity and may be settled in cash, shares of Class A common stock, or a combination thereof, at the Company’s election and subject to certain conditions. In the event of a default, the interest rate increases to 18% per annum. The Company may redeem the notes at a premium of 10% over the greater of (i) the value of the shares otherwise issuable upon conversion and (ii) the value of the note’s outstanding principal. In a bankruptcy-related default, the notes are redeemable at a 25% premium, unless waived by the holder.
The 2025 July Unsecured SPA Notes are convertible at the option of the holder into shares of the Company’s Class A common stock at an initial fixed conversion price of $262.50 per share, as adjusted for the reverse Stock Split, subject to customary anti-dilution adjustments and full ratchet anti-dilution price protection. The number of shares issuable upon conversion is determined by dividing the outstanding principal and accrued interest, together with an 8% premium, by the conversion price. The notes also include an alternate conversion feature that permits the holder to convert at the lower of (i) the then-effective conversion price or (ii) the greater the floor price and the lowest VWAP of the Class A common stock during the five trading days immediately preceding the conversion notice. If a conversion under the alternate mechanism would result in issuance below the floor price, the Company must either settle the difference in cash or increase the principal balance of the note by the shortfall amount. The floor price is subject to reduction at the Company's discretion and was $5.00 per share, as adjusted for the reverse Stock Split, as of September 30, 2026.
The 2025 July Unsecured SPA Investors were issued warrants (the “2025 July Unsecured SPA Warrants”) equal to 33% of the shares issuable upon conversion of the aggregate principal amount under the 2025 July Unsecured SPA Notes funded. The 2025 July Unsecured SPA Warrants are exercisable immediately with a term of five years. The 2025 July Unsecured SPA Warrants are subject to a full ratchet anti-dilution price protection similar to that applicable to the 2025 July Unsecured SPA Notes. As of September 30, 2026, the Company’s 2025 July Unsecured SPA Warrants are indexed to the Company’s Class A common stock and meet the requirements for equity classification under the scope exception in ASC 815-40.
The 2025 July Unsecured SPA Investors received a number of shares of Series B Preferred Stock equal to the lesser of (i) the number of shares of common stock into which such purchaser’s notes are convertible, and (ii) such purchaser’s pro rata share (based on commitment percentage) of an aggregate cap of 6,813,785 shares of Series B Preferred Stock. See Note 13 Stockholders’ Equity for further details regarding the Series B Preferred Stock.
Amendments and Modifications
On August 21, 2025, the Company and the required purchasers under the 2025 July Unsecured SPA entered into an amendment to the 2025 July Unsecured SPA. Pursuant to the amendment, the aggregate Note Commitment Amount under the 2025 July Unsecured SPA was increased from $82.0 million to $83.5 million, and the Commitment Annex to the 2025 July Unsecured SPA was amended and restated in its entirety to reflect such increase.
On July 9, 2026, the Company amended and restated the 2025 July Unsecured SPA to divide the remaining Subsequent Closing into eight Subsequent Closings, with the eighth designated as the Final Closing. Each Subsequent Closing generally occurs within three business days after receipt of at least $5.0 million of additional funding under the note commitments since the preceding closing, or at another agreed time. Notes issued at each Subsequent Closing correspond to funding since the preceding closing, with the remaining commitment issued at the Final Closing. The amendment removed the covenant to use commercially reasonable efforts to file and obtain effectiveness of registration statements for Initial Note conversion shares and maintain their effectiveness, the VWAP Requirement for Subsequent Closings, and the lock-up applicable to Subsequent Closing securities; other applicable closing conditions and transfer restrictions remained unchanged.
For the Initial Notes and related warrants, the July 9, 2026 amendment changed the Subsequent Closing price-reset event to the Final Closing. The new amended and restated notes retain the Final Closing and stockholder-approval price resets, but do not include the initial registration-effectiveness reset. The second and third closings under the 2025 July Unsecured SPA
occurred on July 31 and August 21, 2026, respectively. Neither closing constituted the Final Closing or triggered the related conversion-price reset.
Note Conversion and exercise price re-set and conversion floor reduction
Pursuant to the terms of the 2025 July Unsecured SPA Notes, on September 19, 2025, the fixed conversion price of the 2025 July Unsecured SPA Notes and the exercise price of the related common stock warrants were reset to 100% and 120%, respectively, of the closing price of the Company’s Class A common stock on the trading day immediately prior to the receipt of stockholder approval for the related private placement. This reset did not trigger any price-based anti-dilution provisions of other outstanding convertible instruments.
During the three months ended September 30, 2026, the Company exercised its contractual right to reduce the price floor of the 2025 July Unsecured SPA Notes on multiple occasions, reducing it to $7.50 per share, as adjusted for the Reverse Stock Split, on July 23, 2026, and to $5.00 per share on July 27, 2026. Subsequent reductions to $1.50 and $1.00 per share on September 22 and September 24, 2026, respectively, were rescinded on September 26, 2026. Accordingly, the floor price was $5.00 per share as of September 30, 2026. Conversions of the Initial Notes during the period were effected pursuant to the alternate conversion feature.
Anti-Dilution Adjustments
During the three months ended September 30, 2026, certain issuances of Class A Common Stock under the Company’s at-the-market offering program triggered full ratchet anti-dilution adjustments to the 2025 July Unsecured SPA Notes. Under the anti-dilution provisions of the 2025 July Unsecured SPA Notes, this reduction was treated as a dilutive issuance and triggered the full ratchet anti-dilution price protection for the outstanding 2025 July Unsecured SPA Notes. Accordingly, after giving effect to the contractual floor-price provisions, the applicable conversion price of the outstanding 2025 July Unsecured SPA Notes as of September 30, 2026 was $5.00 per share, as adjusted for the Reverse Stock Split.
Summary of 2025 July Unsecured SPA Notes Activity
As of September 30, 2026, the fair value of the outstanding 2025 July Unsecured SPA Notes, was approximately $7.4 million compared to $26.8 million as of December 31, 2025.
On July 31 and August 21, 2026, Lumina exchanged previously funded Unsecured Convertible Notes into 2025 July Unsecured SPA Notes with stated principal amounts of $5.1 million and $5.0 million, respectively. The new notes mature on July 31, 2031 and August 21, 2031, respectively. These closings did not result in additional cash proceeds on the exchange dates. On September 30, 2026, the Company paid Lumina $0.5 million in settlement of $0.4 million of principal plus interest and premiums on 2025 July Unsecured SPA Notes. The cash settlement was separate from conversions into Class A Common Stock.
During the three and nine months ended September 30, 2026, the Company received no net cash proceeds, after original issue discounts, in exchange for the issuance of 2025 July Unsecured SPA Notes. During the same periods, the Company converted debt with principal amounts of $8.2 million and $31.0 million into 1,373,161 and 1,979,577 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of 2025 July Unsecured SPA Notes into Class A Common Stock resulted in loss on extinguishment of $3.3 million and $12.8 million for the respective periods. For the three and nine months ended September 30, 2026, the Company recognized gains of $4.6 million and $1.9 million from the fair value remeasurement of 2025 July Unsecured SPA Notes under ASC 825, respectively, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
During the three and nine months ended September 30, 2025, the Company received net cash proceeds of $39.2 million, after original issue discounts, in exchange for the issuance of 2025 July Unsecured SPA Notes. For the three and nine months ended September 30, 2025, the Company recognized a gain of $9.2 million from the fair value remeasurement of 2025 July Unsecured SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
2026 May Convertible SPA Notes
Overview and Terms
On May 15, 2026, the Company entered into a securities purchase agreement (the “2026 May Convertible SPA”) with certain accredited investors (collectively, the “2026 May Convertible Notes SPA Investors”), pursuant to which the Company issued and sold senior convertible promissory notes in an aggregate original principal amount of $25.0 million (the “2026 May Convertible SPA Notes”). The 2026 May Convertible SPA Notes define the outstanding principal value as 108% of the stated principal amount. Accordingly, the $25.0 million funded amount resulted in an aggregate unpaid principal balance of $27.0 million, with the $2.0 million difference reflected as an original issue discount.
The original terms below continue to apply to the note held by Alto Opportunity Master Fund, SPC ("Alto"). The note held by About Investment Pte. Ltd. ("About") is subject to the September 2026 amendment described below.
At the closing, 50% of each investor’s commitment was remitted directly to the Company and the remaining 50% was deposited into a separate holder-controlled deposit account, in which the applicable holder holds a first-priority security interest. Amounts held in the holder-controlled accounts are classified as restricted cash until released to the Company. Each holder controls the release of the applicable funds pursuant to a deposit account control agreement. The funds are released to the Company only upon conversion of the related notes, and only to the extent the cash held in the account exceeds the amount required to secure the portion of each note that remains outstanding.
The 2026 May Convertible SPA Notes mature on May 15, 2027 and bear interest at 8% per annum on the outstanding principal value. Interest is payable in shares of Class A Common Stock upon each conversion as part of the amount converted, with any remaining accrued and unpaid interest payable in cash at maturity. In the event of a default, the interest rate increases to 15% per annum. Any amounts not paid when due bear an additional 18% per annum late charge, except to the extent such amount is simultaneously accruing interest at the default rate. The amount payable upon a conversion, redemption or other repayment also includes a make-whole amount equal to the additional interest that would have accrued through the maturity date.
The 2026 May Convertible SPA Notes are convertible at the option of the holders at any time into shares of the Company’s Class A Common Stock at a fixed conversion price of $58.23 per share, as adjusted for the Reverse Stock Split, subject to customary adjustments and full-ratchet anti-dilution price protection. The number of shares issuable upon conversion is determined by dividing the applicable outstanding principal value, accrued and unpaid interest, the make-whole amount, late charges and other amounts due under the notes (“the Conversion Amount”), by the applicable conversion price. Alternatively, the holders may convert at an alternate conversion price equal to the lower of (i) the then-effective fixed conversion price and (ii) the greater of the floor price and the lowest of the five daily VWAPs of the Class A Common Stock during the five consecutive trading days immediately preceding the applicable conversion notice. The Company may reduce the floor price, subject to the rules of the applicable principal market and specified notice requirements. On July 23, 2026, the Company reduced the floor price from $23.29 to $11.55 per share, as adjusted for the Reverse Stock Split.
The Company may, on one occasion and provided that no Equity Conditions Failure exists, redeem all, but not less than all, of the outstanding 2026 May Convertible SPA Notes for cash. The redemption price equals the greater of (i) 110% of the Conversion Amount and (ii) the amount the holder would have received if the holder had converted the notes into shares of Class A Common Stock and sold such shares at the highest closing sale price during the applicable measurement period (“the market-based amount”).
The holder may require the Company to redeem all or a portion of the 2026 May Convertible SPA Notes in cash upon the occurrence of certain specified events. Upon an Event of Default other than a bankruptcy-related Event of Default, the redemption price equals the greater of (i) 108% of the applicable Conversion Amount and (ii) the market-based amount described above. Upon a Change of Control, the redemption price equals the greatest of (i) 108% of the applicable Conversion Amount, (ii) the market-based amount described above, and (iii) an amount determined by reference to the per-share cash and non-cash consideration payable to common stockholders in the Change of Control. If the Company fails to cure a Floor Breach Event within the contractual cure period, the holder may require redemption at the applicable Conversion Amount, without premium. Upon a bankruptcy-related Event of Default, the outstanding 2026 May Convertible SPA Notes automatically become immediately due and payable, without further action by the holder, at 108% of the sum of Outstanding Principal Value, accrued and unpaid interest, make-whole interest, and any applicable late charges, unless waived by the holder in whole or in part.
On September 15, 2026, the Company and About amended the About note and related deposit account control agreement to permit prepayment from the reserve collateral. The Company paid $5.0 million of reserve collateral to About on September 4, 2026. Under the amendment, the remaining $5.9 million, including $0.4 million of interest, is payable in cash within six
months of the effective date as payment in full. Further accrual of the original 8% annual interest ceased, and the ongoing conversion and share-reserve obligations terminated. Interest accrued before the effective date and the contractual make-whole amount remained payable. The original May 15, 2027 maturity was replaced for the remaining About payoff and Alto's note terms remained unchanged.
The Company elected the fair value option under ASC 825 for the 2026 May Convertible SPA Notes. The September 15 amendment was accounted for as an extinguishment of About’s original note because it eliminated a substantive conversion option. The original note was remeasured to fair value immediately before extinguishment and derecognized, and the replacement obligation was initially recognized at fair value, resulting in a gain on extinguishment of $0.2 million. The Company also elected the fair value option for the replacement obligation. Changes in fair value are recognized in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
The Company elected the fair value option under ASC 825 for the 2026 May Convertible SPA Notes. Changes in fair value are recognized in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Transaction costs associated with the issuance of the notes were expensed as incurred.
Summary of Activity
As of September 30, 2026, the fair value of the outstanding 2026 May Convertible SPA Notes was $15.4 million. There were no 2026 May Convertible SPA Notes outstanding as of December 31, 2025.
During the three and nine months ended September 30, 2026, the Company received net cash proceeds of zero and $25.0 million, respectively, after original issue discounts, in exchange for the issuance of 2026 May Convertible SPA Notes. During the same periods, the Company converted debt with principal amounts of $1.3 million and $1.3 million into 228,454 and 228,454 shares of Class A Common Stock, as adjusted for the Reverse Stock Split, respectively. The conversion of 2026 May Convertible SPA Notes into Class A Common Stock resulted in loss on extinguishment of $0.1 million and $0.1 million for the respective periods. For the three and nine months ended September 30, 2026, the Company recognized gains of approximately $3.4 million and $4.9 million, respectively from the fair value remeasurement of the 2026 May Convertible SPA Notes under ASC 825, which was recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
There were no transactions involving the 2026 May Convertible SPA Notes during the three and nine months ended September 30, 2025, as the notes had not yet been issued.
Secured Streeterville Notes
Overview and Terms
On April 17, 2026, the Company entered into a notes purchase agreement (the “Streeterville NPA”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which the Company issued a promissory note with an original principal amount of $15.8 million (the “A-1 Note”) and a secured promissory note with an original principal amount of $30.0 million (the “B Note” and, together with the A-1 Note and any additional notes issued upon an exchange of the B Note, the “Secured Streeterville Notes”). Streeterville paid an aggregate purchase price of $45.0 million, of which $15.0 million was remitted to the Company and $30.0 million was deposited into a segregated deposit account subject to a deposit account control agreement. The A-1 Note includes an original issue discount of $0.8 million included in its original principal balance.
The A-1 and B Secured Streeterville Notes mature on April 17, 2028, which is 24 months after their purchase price date. Each additional A Note issued upon exchange of the B Note matures on the greater of (i) 12 months after its issuance and (ii) the remaining term of the B Note. The A Notes bear interest at a rate of 9% per annum (non-compounding), and the B Note bears interest at a rate of 3.5% per annum, compounding daily. If an event of default occurs and is continuing, the applicable interest rate increases to the lesser of 18% per annum or the maximum rate permitted by applicable law. The Company may prepay the A Notes and B Note at 110% and 105%, respectively, of the portion of the outstanding balance being prepaid.
If the A-1 Note remains outstanding on the 180-day anniversary of its purchase price date, a one-time monitoring fee equal to 25% of the then-outstanding balance will be added to the outstanding balance of the A-1 Note. For any additional A Note issued more than six months after April 17, 2026, the monitoring fee is included in the note's initial principal balance upon issuance. The monitoring fee, and accrued interest thereon, are subject to pro rata forgiveness only if the Company makes cash payments on the A Notes.
Following a specified trigger event, Streeterville may increase the outstanding balance of each affected A Notes by 7.5%, on one occasion during the term of that A Note. Upon an event of default, the Company must pay the outstanding balance of the applicable Secured Streeterville Notes in cash, and in the case of the A Notes, at an amount reflecting any such 7.5% increase.
Beginning on October 17, 2026, Streeterville may require the Company to redeem up to an aggregate of $0.8 million per month under the outstanding A Notes. The applicable redemption amount, together with make-whole interest calculated as though the redeemed amount remained outstanding through maturity, may be settled in cash or shares of Class A Common Stock, at the Company’s election and subject to specified conditions, with the number of shares determined by reference to the Nasdaq Minimum Price on the applicable redemption date.
Beginning on October 17, 2026, the Secured Streeterville Notes also permit additional limited redemptions when the trading price of the Company’s Class A Common Stock is at least 15% greater than the applicable Nasdaq Minimum Price. The amount subject to a limited redemption is limited to 5% of the applicable cumulative daily dollar trading volume and may not exceed $5.0 million in aggregate for all outstanding notes. Limited redemptions are applied first to the A Notes; the B Note becomes subject to limited redemption only after the aggregate outstanding balance of the A Notes has been satisfied. Limited redemptions are settled in shares of Class A Common Stock, with the number of shares determined by dividing the limited redemption amount, including applicable make-whole interest, by the Nasdaq Minimum Price. For both monthly and limited redemptions, if the Nasdaq Minimum Price is below the contractual floor price, Streeterville may require the applicable redemption amount to be paid in cash. The contractual floor price is $9.05 per share, as adjusted for the Reverse Stock Split.
Subject to specified conditions, and generally following a reduction of at least $0.3 million in the aggregate outstanding balance of the A Notes, the Company may exchange a portion of the B Note — up to one-half of the applicable reduction amount — for an additional A Note. Each additional A Note generally has the same interest rate, original issue discount percentage and other economic terms as the A-1 Note. Upon completion of a note exchange, an amount equal to the portion of the B Note exchanged becomes eligible for release from the deposit account. Similarly, as the B Note is redeemed in shares of Class A Common Stock upon a limited redemption, an amount corresponding to the portion of the B Note so redeemed becomes eligible for release from the deposit account.
The $30.3 million held in the secured deposit account is classified as non-current restricted cash until released in accordance with the Streeterville NPA, the B Note and the deposit account control agreement. Release is contingent on the redemption or exchange of the B Note, which cannot occur before October 17, 2026 and is subject to future events outside the Company's control; as a result, the Company has no present ability to compel release within twelve months and cannot reliably determine the amount or timing of any release. Under the deposit account control agreement, Streeterville has the right to direct the disposition of the funds, which are subject to a first-priority security interest in favor of Streeterville. The B Note is also secured by a first-position pledge of all membership interests owned by the Company in FFAI Holdings, LLC. The Company’s obligations under the Secured Streeterville Notes are guaranteed by certain subsidiaries of the Company.
The Company elected the fair value option under ASC 825 for the Secured Streeterville Notes. Changes in fair value are recognized in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Transaction costs associated with the issuance of the Secured Streeterville Notes were expensed as incurred.
Summary of Secured Streeterville Notes Activity
As of September 30, 2026, the fair value of the outstanding Secured Streeterville Notes was approximately $45.9 million. There were no Secured Streeterville Notes outstanding as of December 31, 2025.
During the three and nine months ended September 30, 2026, the Company received aggregate proceeds of zero and $45.0 million after original issue discounts, in exchange for Secured Streeterville Notes. Of the proceeds received, $30.0 million was deposited into the secured deposit account. There were no principal repayments, redemptions, note exchanges or settlements in shares of Class A Common Stock during the three and nine months ended September 30, 2026. Accordingly, the Company did not recognize a gain or loss on extinguishment related to the Secured Streeterville Notes during either period.
For the three and nine months ended September 30, 2026, the Company recognized losses of approximately $2.8 million and $0.9 million related to changes in the fair value of the Secured Streeterville Notes under ASC 825. The loss was recognized in Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.
There were no transactions involving the Secured Streeterville Notes during the three and nine months ended September 30, 2025, as the notes had not yet been issued.
2025 Convertible Note - FFR
On April 28, 2025, FFR entered into a Secured Convertible Note (the “2025 Convertible Note - FFR”) with Alpha Capital Anstalt (“Alpha”, or “Holder”), pursuant to which FFR issued to Alpha a non-interest-bearing note with a principal of approximately $0.3 million, and an original issue discount (“OID”) of 20%, in exchange for approximately $0.2 million cash, net of immaterial issuance costs. The Note is convertible at any time at Alpha’s option, into shares of the FFR’s common stock at a price equal to $2.25 per share (the “Conversion Price”), subject to customary adjustments. The Convertible Note bears no stated interest, and is due on January 28, 2026 (the “Maturity Date”). The Company concluded that the 2025 Convertible Note - FFR did not contain a substantial premium and therefore elected to account for the instrument under the fair value option in accordance with ASC 825-10-15-4.
On June 4, 2025, prior to the acquisition, FFR repaid approximately $0.1 million in principal at the request of Alpha. FFR repaid the remaining outstanding balance of $0.1 million at maturity, on January 28, 2026. During the three and nine months ended September 30, 2026, FFR recognized an immaterial gain from the fair value remeasurement of the 2025 Convertible Note - FFR. no balance remained outstanding as of September 30, 2026.